Proteomics reveal biomarkers for diagnosis, disease activity and long-term disability outcomes in multiple sclerosis

Abstract excerpt

Sensitive and reliable protein biomarkers are needed to predict disease trajectory and personalize treatment strategies for multiple sclerosis (MS). Here, we use the highly sensitive proximity-extension assay combined with next-generation sequencing (Olink Explore) to quantify 1463 proteins in cerebrospinal fluid (CSF) and plasma from 143 people with early-stage MS and 43 healthy controls. With longitudinally...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Multiple Sclerosis Research Studies
• Share to Neuroinflammation and Neurodegeneration Mechanisms
• Share to Systemic Sclerosis and Related Diseases